GO:0032311 angiogenin-PRI complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032311 describes the angiogenin-PRI complex, a stable heterodimer formed by angiogenin (ANG) and placental ribonuclease inhibitor (PRI, also known as RNH1).
• Formation of this complex simultaneously abolishes both the ribonucleolytic and angiogenic activities of angiogenin, as demonstrated in human placental extracts.
• PRI binds directly to the active site of angiogenin, blocking substrate access and preventing receptor-mediated angiogenic signaling.
• The complex is a paradigm for post-translational control of a secreted growth factor by a cytosolic inhibitor, with implications for angiogenesis, cancer, and inflammation.
• Dysregulation of the angiogenin-PRI balance has been linked to systemic inflammation and oxidative stress in neuropsychiatric conditions such as obsessive-compulsive disorder.
• The complex is a candidate biomarker and therapeutic target in angiogenesis-dependent diseases, including diabetic macular edema, where anti-VEGF responses are under investigation.
Description
The angiogenin-PRI complex (GO:0032311) is a cellular component defined as a stable heterodimer of angiogenin and placental ribonuclease inhibitor (PRI). Angiogenin is a secreted ribonuclease that promotes blood vessel formation, while PRI is a cytosolic leucine-rich repeat protein that binds with high affinity to angiogenin. The interaction between these two proteins prevents angiogenin from binding to its receptor and stimulating angiogenesis, thereby acting as a molecular brake on angiogenic signaling. This complex is of broad interest because it exemplifies how a secreted growth factor can be sequestered and inactivated by an intracellular inhibitor, a mechanism that may be exploited for therapeutic intervention in cancer and other angiogenesis-dependent diseases. Recent proteomic studies have also implicated the angiogenin-PRI axis in systemic inflammation and oxidative stress, expanding its relevance beyond vascular biology. Understanding the structure, assembly, and regulation of this complex is therefore important for researchers in cell biology, oncology, and inflammation.
angiogenin-PRI complex At A Glance
| GO ID | GO:0032311 |
|---|---|
| GO term | angiogenin-PRI complex |
| Ontology | cellular_component |
| Synonym | angiogenin-placental ribonuclease inhibitor complex |
| Major function | Inhibits angiogenin-mediated angiogenesis and ribonucleolytic activity |
| Complex type | Stable heterodimer |
| Components | Angiogenin (ANG) and placental ribonuclease inhibitor (PRI/RNH1) |
| Biological context | Angiogenesis regulation, ribonuclease inhibition, inflammation |
What Is GO:0032311?
The angiogenin-PRI complex is a stable heterodimer composed of one molecule of angiogenin and one molecule of placental ribonuclease inhibitor (PRI). This complex forms when PRI binds to the active site of angiogenin, effectively blocking its ribonucleolytic activity and preventing angiogenin from interacting with its receptor to stimulate angiogenesis.
Why Is angiogenin-PRI complex Important in Cell Biology?
The angiogenin-PRI complex is important because it represents a key control point in angiogenesis, a process fundamental to tumor growth, wound healing, and various vascular diseases. By sequestering angiogenin, PRI prevents the activation of endothelial cells and the formation of new blood vessels. This regulatory mechanism is critical for maintaining tissue homeostasis, and its dysregulation can contribute to pathological angiogenesis, inflammation, and cancer progression.
• Provides a molecular mechanism for negative regulation of angiogenesis by a secreted ribonuclease inhibitor.
• Serves as a model for understanding how intracellular inhibitors can neutralize extracellular growth factors.
• Implicated in cancer biology, where angiogenin overexpression promotes tumor angiogenesis and PRI may act as a tumor suppressor.
• Linked to inflammatory and oxidative stress pathways in neuropsychiatric disorders such as obsessive-compulsive disorder.
• Relevant to diabetic macular edema, where anti-VEGF therapies target angiogenesis and biomarkers like miRNAs in tear fluid are being explored.
• Offers a potential therapeutic target for modulating angiogenesis in ischemic and neoplastic diseases.
• Highlights the importance of protein-protein interactions in controlling enzymatic and signaling activities.
• Provides a paradigm for studying ribonuclease inhibitor families and their roles in cellular protection.
What Happens During angiogenin-PRI complex?
Angiogenin Secretion and Receptor Binding
In simple terms: Angiogenin is released from cells and can bind to receptors on endothelial cells to trigger new blood vessel growth.
Angiogenin is a secreted protein that, upon binding to its receptor on endothelial cells, stimulates angiogenesis. This process involves activation of signaling pathways that promote cell migration, proliferation, and tube formation. However, when PRI is present in the extracellular environment or within cells, it can bind to angiogenin and prevent this interaction.
PRI Binding to Angiogenin
In simple terms: PRI grabs onto angiogenin and blocks its active site, stopping it from working.
Placental ribonuclease inhibitor (PRI) forms a tight, non-covalent complex with angiogenin by inserting into its active site. This binding is highly specific and results in the inhibition of angiogenin's ribonucleolytic activity, which is essential for its angiogenic function.
Inhibition of Ribonucleolytic Activity
In simple terms: Once PRI is attached, angiogenin can no longer cut RNA, which is needed for its blood vessel-promoting effects.
The ribonucleolytic activity of angiogenin is required for its angiogenic activity. By binding to the active site, PRI abolishes this enzymatic activity, as shown by the loss of both ribonucleolytic and angiogenic functions in the presence of PRI.
Prevention of Receptor-Mediated Angiogenesis
In simple terms: Because PRI blocks angiogenin, the signal to grow new blood vessels is never sent.
The angiogenin-PRI complex prevents angiogenin from binding to its receptor on endothelial cells, thereby inhibiting the downstream signaling cascade that leads to angiogenesis. This mechanism effectively neutralizes the pro-angiogenic effects of angiogenin.
Key Genes Involved in GO:0032311 angiogenin-PRI complex
The following genes and proteins are directly involved in the formation, regulation, and function of the angiogenin-PRI complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ANG | Encodes angiogenin, a secreted ribonuclease and angiogenic factor | Central to angiogenesis; target for cancer and vascular research |
| RNH1 | Encodes placental ribonuclease inhibitor (PRI), a cytosolic inhibitor of angiogenin | Key regulator of angiogenin activity; potential tumor suppressor |
| VEGFA | Encodes vascular endothelial growth factor A, a master regulator of angiogenesis | Often studied alongside angiogenin in angiogenesis assays |
| KDR | Encodes VEGFR2, receptor for VEGF and possibly angiogenin | Mediates angiogenic signaling; target of anti-angiogenic therapies |
| FLT1 | Encodes VEGFR1, a decoy receptor for VEGF | Modulates angiogenesis; relevant to diabetic macular edema |
| HIF1A | Hypoxia-inducible factor 1-alpha, upstream regulator of angiogenic genes | Links hypoxia to angiogenin and VEGF expression |
| AKT1 | Serine/threonine kinase in PI3K/AKT pathway | Downstream of angiogenin signaling; promotes cell survival |
| MAPK1 | Mitogen-activated protein kinase 1 | Involved in angiogenin-induced endothelial cell proliferation |
| RNH1 | Ribonuclease inhibitor 1 (same as PRI) | Directly binds and inhibits angiogenin |
| ANG | Angiogenin (same as above) | Forms complex with PRI |
| PLXNB2 | Plexin B2, a receptor for angiogenin | Mediates angiogenin-induced angiogenesis |
| SERPINA1 | Alpha-1 antitrypsin, may interact with angiogenin | Potential modulator of angiogenin activity |
| IL6 | Interleukin-6, inflammatory cytokine | Linked to systemic inflammation in OCD where angiogenin-PRI axis is implicated |
| TNF | Tumor necrosis factor | Inflammatory mediator; may influence angiogenin expression |
| NGF | Nerve growth factor | Neurotrophic factor; potential crosstalk with angiogenin in neurons |
| BDNF | Brain-derived neurotrophic factor | Implicated in OCD and may interact with angiogenin pathways |
| VEGFB | Vascular endothelial growth factor B | Angiogenesis-related; potential co-target with angiogenin |
| PGF | Placental growth factor | Pro-angiogenic factor; studied in diabetic macular edema |
How Is angiogenin-PRI complex Regulated?
The formation of the angiogenin-PRI complex is regulated primarily by the availability and subcellular localization of PRI. PRI is a cytosolic protein, while angiogenin is secreted; thus, complex formation occurs when angiogenin is internalized or when PRI is released from damaged cells. The balance between angiogenin and PRI levels can be altered by inflammatory cytokines and oxidative stress, as suggested by proteomic studies in obsessive-compulsive disorder. Additionally, hypoxia and growth factors can upregulate angiogenin expression, potentially overwhelming PRI inhibition.
angiogenin-PRI complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ANG | Cancer, angiogenesis | Xenograft models with ANG overexpression or knockout |
| RNH1 | Cancer, inflammation | RNH1 knockout or overexpression in cell lines |
| ANG/RNH1 | Obsessive-compulsive disorder | Patient-derived serum proteomics and neuronal cell models |
| VEGFA | Diabetic macular edema | Retinal endothelial cells and animal models of diabetes |
| ANG | Neurodegeneration | Neuronal cultures and knockout mice |
Cancer and Angiogenesis
Angiogenin is overexpressed in many cancers and promotes tumor angiogenesis. The angiogenin-PRI complex acts as a natural inhibitor of this process, and loss of PRI function could contribute to tumor progression. Targeting the angiogenin-PRI interaction may therefore be a therapeutic strategy to limit angiogenesis in tumors.
Inflammatory and Neuropsychiatric Disorders
Recent proteomic analysis of serum from drug-free obsessive-compulsive disorder patients revealed multifactorial cellular function impairment and aggravated systemic inflammation, with potential involvement of angiogenin and its inhibitor. This suggests that the angiogenin-PRI axis may be a biomarker or therapeutic target in neuropsychiatric conditions characterized by inflammation.
Diabetic Macular Edema
Diabetic macular edema is a complication of diabetic retinopathy driven by angiogenesis and vascular leakage. Anti-VEGF therapies are standard, but response varies. MicroRNA profiles in tear fluid have been studied to predict anti-VEGF response, and angiogenin-PRI balance may influence treatment outcomes.
From angiogenin-PRI complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PRI increase angiogenesis? | RNH1 knockout endothelial cells or mice |
| Can angiogenin-PRI complex formation be monitored in live cells? | Knock-in of fluorescent tags on ANG and RNH1 |
| What is the effect of a point mutation in ANG that prevents PRI binding? | Point-mutation knock-in of ANG active site mutants |
| How does overexpression of PRI affect tumor growth? | Xenograft models with RNH1 overexpression |
| What is the interactome of the angiogenin-PRI complex? | Proximity labeling or co-immunoprecipitation followed by mass spectrometry |
| Can CRISPR screening identify regulators of the complex? | Genome-wide CRISPR knockout library screening |
How to Study the angiogenin-PRI complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between angiogenin and PRI | Confirm complex formation in cell lysates |
| Surface plasmon resonance | Binding affinity and kinetics | Quantify angiogenin-PRI interaction |
| Ribonuclease activity assay | Enzymatic activity of angiogenin | Assess inhibition by PRI |
| Endothelial tube formation | Angiogenic potential | Test functional effects of the complex |
| iTRAQ proteomics | Relative protein abundance | Identify biomarkers in disease |
| MicroRNA profiling | Expression of regulatory miRNAs | Predict response to anti-VEGF therapy |
| CRISPR knockout screening | Gene essentiality and modifiers | Discover regulators of the complex |
| Live-cell imaging | Subcellular localization and dynamics | Track complex assembly in real time |
Proteomic Analysis
Mass spectrometry-based proteomics, such as iTRAQ, can quantify angiogenin and PRI levels in biological samples and identify post-translational modifications that regulate complex formation.
Ribonuclease Activity Assays
The ribonucleolytic activity of angiogenin can be measured using RNA substrates, and the inhibitory effect of PRI can be assessed by adding recombinant PRI to the assay.
Angiogenesis Assays
Endothelial cell tube formation, migration, and proliferation assays can be used to evaluate the functional impact of the angiogenin-PRI complex on angiogenesis.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify genes that modulate the formation or stability of the angiogenin-PRI complex, offering unbiased insights into its regulation.
How CRISPR Can Be Used to Study GO:0032311 angiogenin-PRI complex
Knockout
CRISPR knockout of ANG or RNH1 can be used to study the consequences of losing the angiogenin-PRI complex. ANG knockout reduces angiogenesis, while RNH1 knockout increases angiogenin activity and may enhance angiogenesis.
Point Mutation
Point mutations in the active site of ANG that disrupt PRI binding can be introduced to study the structural requirements for complex formation and to create constitutively active angiogenin variants.
Knock-in
Knock-in of epitope tags or fluorescent proteins into the endogenous ANG or RNH1 loci allows for visualization and purification of the complex without altering its regulation.
Overexpression
Overexpression of RNH1 can be achieved by CRISPR activation or lentiviral delivery to test whether increasing PRI levels suppresses angiogenesis in vitro and in vivo.
How EDITGENE Supports angiogenin-PRI complex Research
Researchers studying angiogenin-PRI complex-related genes often need to determine whether a candidate gene is causally involved in complex formation, angiogenesis, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of this pathway.
Contact EDITGENE today to design your custom CRISPR model for angiogenin-PRI complex research.
Frequently Asked Questions About angiogenin-PRI complex
What is the angiogenin-PRI complex?
The angiogenin-PRI complex (GO:0032311) is a stable heterodimer of angiogenin and placental ribonuclease inhibitor that prevents angiogenin from stimulating angiogenesis.
What genes are involved in the angiogenin-PRI complex?
The main genes are ANG, which encodes angiogenin, and RNH1, which encodes placental ribonuclease inhibitor (PRI).
How does PRI inhibit angiogenin?
PRI binds to the active site of angiogenin, blocking its ribonucleolytic activity and preventing receptor binding, thereby inhibiting angiogenesis.
What diseases are associated with the angiogenin-PRI complex?
It has been implicated in cancer, inflammatory conditions, obsessive-compulsive disorder, and diabetic macular edema.
Can CRISPR be used to study the angiogenin-PRI complex?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the function of ANG and RNH1.
What methods are used to study the angiogenin-PRI complex?
Common methods include co-immunoprecipitation, surface plasmon resonance, ribonuclease activity assays, and angiogenesis assays.
Is the angiogenin-PRI complex a therapeutic target?
Modulating the complex could be a strategy to control angiogenesis in cancer and other diseases, though more research is needed.
What is the GO term for the angiogenin-PRI complex?
The Gene Ontology term is GO:0032311, under the cellular_component ontology.
How is the angiogenin-PRI complex regulated?
Regulation occurs through the availability of PRI, cellular localization, and inflammatory signals that affect the balance of angiogenin and PRI.
What cell models are available for studying the angiogenin-PRI complex?
EDITGENE provides knockout, point mutation, knock-in, and overexpression cell models for ANG and RNH1, as well as CRISPR library screening services.
Conclusion
The angiogenin-PRI complex (GO:0032311) is a critical regulatory node in angiogenesis, acting as a molecular switch that controls the pro-angiogenic activity of angiogenin. Its formation blocks both the ribonucleolytic and receptor-mediated functions of angiogenin, with implications for cancer, inflammation, and vascular diseases. Continued research using advanced CRISPR models and proteomic approaches will further elucidate its role and therapeutic potential.
References
- 1. Shapiro R et al.. 1987. Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin.. Proc Natl Acad Sci U S A 84(8):2238-41 PMID: 3470787
- 2. Lee FS et al.. 1989. Binding of placental ribonuclease inhibitor to the active site of angiogenin.. Biochemistry 28(8):3556-61 PMID: 2742853
- 3. Deng M et al.. 2024. iTRAQ-Based Serum Proteomic Analysis Reveals Multifactorial Cellular Function Impairment and Aggravated Systematic Inflammation in Drug-free Obsessive-Compulsive Disorders.. ACS Chem Neurosci 15(16):3053-3063 PMID: 39120470
- 4. Chan HW et al.. 2020. A Pilot Study on MicroRNA Profile in Tear Fluid to Predict Response to Anti-VEGF Treatments for Diabetic Macular Edema.. J Clin Med 9(9) PMID: 32927780
